Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Yahoo! Finance
Will the recent positive trend continue leading up to its next earnings release, or is Nektar due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Nektar Q4 Loss Wider Than Expected, Revenues Beat Nektar reported an adjusted loss of 22 cents per share for the fourth quarter of 2023, wider than the Zacks Consensus Estimate of a loss of 20 cents. In the year-ago quarter, the company had incurred a loss of 32 cents per share. Total revenues increased 8.5% year over year to $23.9 million during the fourth quarter. Revenues beat the Zacks Consensus Estimate of $17 million. Quarter in Details In the fourth quarter, product sales increased around 25.2% from the year-ago quarter's levels to $5.5 million. Non-cash royalty revenues were $18.1 million, up 2.5% from the year-ago quarter. Non-cash royalty revenues were better than
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test [Seeking Alpha]Seeking Alpha
- Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference [Yahoo! Finance]Yahoo! Finance
- Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferencePR Newswire
- Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata [Yahoo! Finance]Yahoo! Finance
- Nektar Therapeutics (NASDAQ: NKTR) had its price target raised by analysts at Jefferies Financial Group Inc. from $0.50 to $1.00. They now have a "hold" rating on the stock.MarketBeat
NKTR
Earnings
- 3/4/24 - Miss
NKTR
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/17/24 - Form 8-K
- NKTR's page on the SEC website